NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Chalet Hotels to Invest ₹633 Crore for New 330-Room Luxury Hotel in Hyderabad
Chalet Hotels has approved the development of a new luxury hotel in Madhapur, Hyderabad, featuring approximately 330 rooms and 36,255 sq. ft. of retail space. The project involves a total investment of approximately Rs. 6,328 million, which will be funded through a combination of internal accruals and debt. This facility will be the company's third hotel in the Hyderabad market and is expected to be operational by FY2029. The development will be part of a building premises obtained on a warm shell lease, aligning with the company's asset-light expansion strategy.
முக்கிய அம்சங்கள்
Proposed development of a ~330-room luxury hotel in Madhapur, HyderabadIncludes ~36,255 sq. ft. of commercial and retail space within the premisesTotal estimated investment of ~Rs. 6,328 million including security depositsProject completion targeted for FY2029, financed via debt and internal accrualsMarks the company's third hotel property in the Hyderabad region
👀 கவனிக்க வேண்டியவை
Investors should view this as a long-term growth driver that strengthens Chalet's footprint in a key business hub. Monitor the company's debt-to-equity ratio as it executes this capital-intensive project over the next three years.
Marshall Machines Updates on CIRP; CoC Approves 90-Day Extension for Insolvency Process
Marshall Machines Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. Recent Committee of Creditors (CoC) meetings have finalized the issuance of Form G to invite potential resolution applicants and established an evaluation matrix for bids. Crucially, the CoC has approved a 90-day extension for the completion of the CIRP to allow more time for the submission and vetting of resolution plans. The company has also replaced its Interim Resolution Professional with Mavent Restructuring Services LLP to lead the process.
முக்கிய அம்சங்கள்
CoC approved the replacement of the IRP with Mavent Restructuring Service LLP as the Resolution Professional.Issuance of Form G for Expression of Interest (EOI) to identify prospective resolution applicants has been initiated.Approved filing an application for a 90-day extension to the statutory timeline for completing the CIRP.Request for Resolution Plan (RFRP) and Evaluation Matrix for assessing potential bids have been finalized.Ratified various administrative costs including fees for valuers, forensic auditors, and legal counsel.
👀 கவனிக்க வேண்டியவை
Investors should remain highly cautious as equity shareholders typically face significant dilution or total loss of value during insolvency proceedings. Monitor the NCLT's approval of the extension and the quality of resolution plans submitted by prospective applicants.
Shalby Q3 FY26: Consolidated PAT Turns Positive at ₹1.3 Cr; MedTech Revenue Jumps 29% YoY
Shalby Limited reported a marginal 0.6% YoY decline in consolidated revenue to ₹279.4 crores for Q3 FY26, while consolidated PAT turned positive at ₹1.3 crores compared to a loss in the previous year. The core hospital business faced headwinds with a 2.6% revenue decline and lower occupancy of 44%, primarily due to ongoing negotiations with major insurance providers. Conversely, the MedTech segment showed strong momentum with 29% revenue growth and achieved EBITDA breakeven for the first time. The company maintains a stable balance sheet with a net debt of ₹408 crores and a low gearing ratio of 0.41x.
முக்கிய அம்சங்கள்
Consolidated PAT improved to ₹1.3 crores from a loss of ₹3 crores in the same quarter last year.MedTech segment revenue grew 29% YoY to ₹30.38 crores, with EBITDA turning positive at ₹0.7 million.Hospital standalone revenue declined 2.6% YoY to ₹221 crores with occupancy dropping to 44% from 46%.ARPOB (Average Revenue Per Occupied Bed) saw a marginal increase of 1.1% YoY to ₹43,171.Shalby International (Gurgaon) reported revenue of ₹23.9 crores with 51% contribution from international patients.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery in hospital occupancy once insurance negotiations are finalized and track the scalability of the now-profitable MedTech division. The stock remains a watch as the company transitions its medical implant business from a turnaround to a growth phase.
Chalet Hotels Secures Stay from Karnataka HC on Rs 39.56 Cr Property Tax Notice
Chalet Hotels Limited has successfully obtained a stay order from the High Court of Karnataka against a property sale notice issued by the Greater Bengaluru Authority. The dispute involves alleged non-payment of property tax dues amounting to approximately Rs 39.56 crore, which includes interest, penalties, and cess. The notice pertained to the company's property located in Whitefield, Bengaluru. This legal intervention prevents the immediate sale of the asset until the next hearing date, providing temporary relief to the company.
முக்கிய அம்சங்கள்
High Court of Karnataka granted a stay order on the 'Proclamation and Written Notice of Sale' of the Whitefield property.The total disputed amount claimed by the Greater Bengaluru Authority is approximately Rs 39.56 crore.The claim includes principal property tax, interest, penalties, and applicable cess.The stay order remains effective until the next scheduled date of hearing in the Writ Petition filed by the company.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final court ruling as a negative outcome would require a cash outflow of Rs 39.56 crore. The current stay is a positive procedural development that protects the company's Bengaluru asset from immediate liquidation.
Vaishali Pharma to Issue 61.23 Lakh Shares for 33.24% Stake in Kesar Pharma
Vaishali Pharma Limited has issued a postal ballot notice to seek shareholder approval for a preferential allotment of 61.23 lakh equity shares. The shares are priced at Rs. 20 each, representing a total transaction value of approximately Rs. 12.25 crores. This is a non-cash transaction involving a share swap to acquire a 33.24% stake in Kesar Pharma Limited, an associate company. The e-voting period for shareholders is scheduled from February 14 to March 15, 2026.
முக்கிய அம்சங்கள்
Preferential issue of up to 61,23,000 equity shares at an issue price of Rs. 20 per shareTotal consideration of Rs. 12.25 crores to be settled via share swap (non-cash)Acquisition of 21,52,575 shares in Kesar Pharma Limited, representing a 33.24% stakeRelevant date for floor price determination fixed as February 13, 2026E-voting results to be announced on or before March 17, 2026
👀 கவனிக்க வேண்டியவை
Investors should assess the strategic value of consolidating the stake in Kesar Pharma against the equity dilution caused by the new share issuance. Monitor the final approval and subsequent integration of Kesar Pharma's operations.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Shah Alloys Q3 Profit at ₹35.22 Cr Driven by ₹67.46 Cr Asset Sale; Main Plant Closed
Shah Alloys reported a net profit of ₹35.22 Crores for Q3 FY26, a turnaround from a loss of ₹15.26 Crores in the previous year, entirely due to exceptional gains of ₹67.46 Crores from asset and investment sales. Revenue from operations plummeted 80% YoY to ₹10.29 Crores as the company's primary Iron and Steel plant has been shut down since August 2025 due to technology obsolescence. Auditors have issued a qualified opinion, flagging material uncertainty regarding the company's status as a 'Going Concern' and noting the non-provision of ₹36.55 lakhs in bank interest. The company is currently exploring options for its future after liquidating significant plant machinery and its stake in SAL Steel Limited.
முக்கிய அம்சங்கள்
Net Profit of ₹35.22 Crores in Q3 FY26 vs a Loss of ₹15.26 Crores in Q3 FY25, driven by one-time gains.Exceptional items of ₹67.46 Crores include a ₹53.47 Crore gain from selling plant/machinery and a ₹13.98 Crore gain from SAL Steel share sale.Revenue from operations fell sharply to ₹10.29 Crores from ₹51.90 Crores YoY following the closure of the Santej plant.Auditors expressed inability to confirm 'Going Concern' status as the main manufacturing facility is no longer operational.Qualified opinion issued for non-provision of ₹36.55 lakhs in interest on bank loans for the quarter.
👀 கவனிக்க வேண்டியவை
Investors should treat the reported profit as a non-recurring event resulting from asset liquidation rather than operational strength. Given the plant closure and auditor warnings on 'Going Concern' status, the stock carries high risk and requires a cautious approach until a new business model is established.
Halder Venture Limited reported a standalone net profit of ₹2.17 crore for Q3 FY26, a sharp decline from ₹13.45 crore in the same quarter last year, though it showed sequential improvement from Q2. The company has approved a strategic acquisition of a 52% stake in Inqube Technologies for ₹30.16 crore to diversify into Agri-ERP and carbon credit markets. Operationally, the company has started packaging at its Haldia unit, capitalizing ₹22.45 crore. However, auditors have raised concerns regarding a pending ₹6.05 crore dividend from a foreign subsidiary that remains uncollected.
முக்கிய அம்சங்கள்
Standalone Net Profit for Q3 FY26 at ₹2.17 crore, down 83.8% YoY from ₹13.45 crore.Approved acquisition of 52% stake in Inqube Technologies Private Limited for ₹30.16 crores.Revenue from operations fell to ₹73.63 crore in Q3 FY26 from ₹286.97 crore in Q3 FY25.Capitalized ₹22.45 crore following the operationalization of packaging units at the Haldia Manufacturing Unit.Auditors highlighted a potential impairment risk for ₹6.05 crore in dividend income receivable from a foreign subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the execution of the Inqube acquisition and the recovery of the ₹6.05 crore dividend from the foreign subsidiary. While the YoY earnings drop is concerning, the operationalization of the Haldia unit and the new tech-focused acquisition are key long-term growth drivers to track.
Halder Venture Fined ₹5.43 Lakh by BSE for Board Composition Non-Compliance
Halder Venture Limited has been penalized ₹5,42,800 by BSE for failing to comply with SEBI Regulation 17(1) regarding board composition during the September 2025 quarter. The company explained that the lapse occurred during the transition period following an amalgamation that made corporate governance norms applicable. Management confirmed that the company became fully compliant on November 14, 2025, and has since filed a waiver application with the exchange. The Board has reviewed the matter and advised the management to exercise abundant caution to ensure future regulatory adherence.
முக்கிய அம்சங்கள்
BSE imposed a total fine of ₹5,42,800 (including ₹82,800 GST) for non-compliance with Regulation 17(1).The company achieved full compliance with board composition requirements on November 14, 2025.A waiver application for the levied fine was filed with BSE on December 1, 2025.The regulatory lapse followed a Scheme of Amalgamation that became effective on January 1, 2025.
👀 கவனிக்க வேண்டியவை
Investors should note the governance lapse but also recognize that the company has already rectified the board composition. Monitor the outcome of the waiver application and ensure no further regulatory delays occur in future filings.
Halder Venture Q3 Net Profit Jumps 105% YoY to ₹2.17 Cr; Announces 52% Stake Buy in InQube
Halder Venture reported a robust performance for Q3 FY26, with standalone revenue growing 28.8% YoY to ₹73.63 crore and net profit doubling to ₹2.17 crore. The company is aggressively expanding, having operationalized its Haldia Manufacturing Unit and announcing a ₹30.16 crore acquisition of a 52% stake in InQube Technologies to enter the Agri-ERP and carbon credit markets. However, investors should monitor an auditor's emphasis regarding a delayed ₹6.05 crore dividend from a foreign subsidiary. For the nine-month period, net profit stands significantly higher at ₹13.45 crore compared to ₹7.15 crore in the previous year.
முக்கிய அம்சங்கள்
Standalone Net Profit for Q3 FY26 surged 105% YoY to ₹217.10 lakhs from ₹105.76 lakhs.Revenue from operations increased by 28.8% YoY to ₹7,363.09 lakhs compared to ₹5,716.92 lakhs.Approved acquisition of 52% stake in InQube Technologies for ₹3,016 lakhs to enter Agri-ERP and carbon credit sectors.Capitalized ₹2,244.57 lakhs for packaging operations at the Haldia Manufacturing Unit during the quarter.Auditor raised an emphasis of matter regarding ₹605.07 lakhs in delayed dividend income from a foreign subsidiary.
👀 கவனிக்க வேண்டியவை
The strong earnings growth and strategic diversification into agri-tech are positive indicators, but investors should seek clarity on the recoverability of the ₹6.05 crore foreign dividend highlighted by auditors.
Vaishali Pharma has approved the issuance of 61.23 lakh equity shares at Rs 20 each via a preferential allotment. This is a non-cash transaction involving a share swap to acquire 21.52 lakh shares of its associate company, Kesar Pharma Limited, at Rs 56.89 per share. The total value of the issuance is approximately Rs 12.25 Crores, resulting in Kesar Pharma holding a 4.48% stake in the company. Additionally, the board has cleared the unaudited financial results for the quarter and nine months ended December 31, 2025.
முக்கிய அம்சங்கள்
Issuance of 61,23,000 equity shares at a price of Rs 20 per shareTotal deal value of Rs 12.246 Crores via share swap for Kesar Pharma stakeAcquisition of 21,52,575 shares of Kesar Pharma Limited at Rs 56.89 per sharePost-allotment, Kesar Pharma Limited will own 4.48% of Vaishali PharmaBoard approved Q3 FY26 results and initiated a postal ballot for shareholder approval
👀 கவனிக்க வேண்டியவை
Investors should evaluate the valuation of Kesar Pharma and the impact of the 4.48% equity dilution on earnings per share. Watch for the detailed Q3 financial performance to assess the company's growth trajectory.
Vaishali Pharma to Issue 61.23 Lakh Shares via Swap for Kesar Pharma Stake
Vaishali Pharma has approved a preferential allotment of 61.23 lakh equity shares at an issue price of ₹20 per share, totaling approximately ₹12.25 crores. This is a non-cash transaction executed via a share swap to subscribe to 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. Post-allotment, Kesar Pharma will hold a 4.48% stake in Vaishali Pharma. The board also approved the unaudited financial results for the quarter ended December 31, 2025.
முக்கிய அம்சங்கள்
Preferential issue of 61,23,000 equity shares at ₹20 each (including ₹18 premium).Total transaction value for the share swap is ₹12,24,60,000.Acquisition of 21,52,575 shares of associate company Kesar Pharma Limited at ₹56.89 per share.Post-issue, Kesar Pharma Limited will hold a 4.48% equity stake in Vaishali Pharma.Board approved Q3 FY26 financial results and initiated a Postal Ballot for shareholder approval.
👀 கவனிக்க வேண்டியவை
Investors should monitor the strategic benefits of increasing the stake in Kesar Pharma and review the Q3 financial results for operational performance. The share swap indicates a consolidation of interests with its associate company.
Simbhaoli Sugars Limited reported its Q3 FY26 results under the supervision of an Interim Resolution Professional (IRP) due to ongoing insolvency proceedings. The auditors have issued a heavily qualified report, noting that the company failed to provide for interest expenses on bank borrowings amounting to ₹8,941.03 Lakhs for the quarter. Total accumulated unprovided interest has now reached a massive ₹2,01,022.71 Lakhs, significantly understating the company's reported losses and liabilities. Furthermore, the company has not conducted mandatory impairment testing for its ₹224 Crore investment in its power subsidiary.
முக்கிய அம்சங்கள்
Unprovided interest on bank borrowings for Q3 FY26 stands at ₹8,941.03 Lakhs, understating net loss.Total accumulated unprovided interest on bank debt reached ₹2,01,022.71 Lakhs (approx ₹2,010 Crore) as of Dec 2025.Auditors flagged unprovided interest of ₹121.63 Crore on delayed sugarcane price payments to farmers.No impairment assessment performed on subsidiary investments (₹224.26 Crore) or Property, Plant & Equipment.Potential contravention of Section 197 regarding management remuneration totaling over ₹411 Lakhs without lender consent.
👀 கவனிக்க வேண்டியவை
Investors should remain extremely cautious as the company is under insolvency (CIRP) and the financial statements do not reflect the true scale of debt. The stock remains highly speculative given the massive unprovided liabilities and ongoing legal proceedings at NCLAT.
Kaushalya Infrastructure Development Corporation Limited has approved its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. The statutory auditors, KASG & Co., issued a limited review report with an unmodified conclusion, indicating no material misstatements were found. The consolidated results incorporate two subsidiaries and three associates, providing a broader view of the group's performance. However, the KIDCO NACC Consortium joint venture remains excluded from consolidation due to discontinued operations.
முக்கிய அம்சங்கள்
Board approved unaudited financial results for the quarter and nine months ended December 31, 2025.Statutory auditors KASG & Co. issued an unmodified limited review report for both standalone and consolidated statements.Consolidated results include 2 subsidiaries (Bengal KDC Housing and KDC Nirman) and 3 associates.Operations of the KIDCO NACC Consortium joint venture remain discontinued and were not consolidated.The board meeting commenced at 02:00 P.M. and concluded at 04:15 P.M. on February 13, 2026.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed profit and loss tables once published to evaluate revenue and margin trends, as the current report only confirms regulatory compliance and auditor sign-off.
HAL Clarifies No Official Communication on Reported 114 Rafale Jet Deal
Hindustan Aeronautics Limited (HAL) has issued a formal clarification regarding a media report in the Times of India concerning a potential deal for 114 Rafale fighter jets. The report suggested that while 20 jets would be delivered in fly-away condition by 2030, the remaining 94 would be manufactured through a Dassault-HAL collaboration in India. HAL has explicitly stated that it has not received any official communication from the Ministry of Defence or Dassault Aviation regarding this specific procurement. This clarification aims to temper market speculation surrounding what the media termed the 'mother of all defence deals'.
முக்கிய அம்சங்கள்
HAL denies receiving official communication regarding the procurement of 114 Rafale jets.Media report claimed 20 jets would be imported and 94 manufactured via Dassault-HAL collaboration.The reported timeline suggested additions to the Indian Air Force fleet by the year 2030.HAL filed this clarification with BSE and NSE to address speculative news dated February 13, 2026.
👀 கவனிக்க வேண்டியவை
Investors should rely on official Ministry of Defence notifications rather than speculative media reports for long-term order book projections. Maintain a watch on official government procurement portals for any formal Request for Proposal (RFP) regarding the MRFA (Multi-Role Fighter Aircraft) program.
HAL Bags Rs 2,312 Crore Order from Ministry of Defence for 8 Dornier 228 Aircraft
Hindustan Aeronautics Limited (HAL) has secured a significant contract worth Rs 2,312 crore from the Ministry of Defence for eight Dornier 228 aircraft. These aircraft are intended for the Indian Coast Guard and include operational role equipment under the 'Buy (Indian)' category. The contract is expected to boost HAL's Kanpur division and strengthen the domestic defense production ecosystem involving various MSMEs. Beyond the initial sale, the agreement ensures long-term revenue through maintenance, repair, and overhaul (MRO) services.
முக்கிய அம்சங்கள்
Total contract value is Rs 2,312 crore for the supply of 8 Dornier 228 aircraft.The order is placed by the Ministry of Defence specifically for the Indian Coast Guard (ICG).The project falls under the 'Buy (Indian)' category, supporting the Aatmanirbhar Bharat initiative.The deal creates sustained opportunities in Maintenance, Repair & Overhaul (MRO) and life cycle support.
👀 கவனிக்க வேண்டியவை
This contract further strengthens HAL's robust order book and provides long-term revenue visibility through both manufacturing and MRO services. Investors should maintain a positive outlook as the company remains a primary beneficiary of India's defense indigenization push.
Shalimar Paints Q3 FY26 Results: EBITDA Losses Halved and Working Capital Cycle Improves by 15 Days
Shalimar Paints reported significant operational improvements for the nine months ended December 31, 2025, despite flat topline growth. The company successfully reduced its EBITDA losses by 50% through enhanced operational efficiencies and a strategic shift toward high-margin products. New product launches were a key driver, contributing 5% to incremental business. Additionally, the company improved its liquidity position by reducing its working capital cycle by 15 days compared to the previous quarter.
முக்கிய அம்சங்கள்
EBITDA losses reduced by 50% through operational efficiencies and better product mix.Working capital cycle improved by 15 days compared to the previous quarter.New products contributed 5% to the incremental business during the nine-month period.Topline growth remained at par with the previous year despite industrial domain challenges.Product mix shifted towards high-margin emulsions and value-added products.
👀 கவனிக்க வேண்டியவை
Investors should view the halving of EBITDA losses and improved working capital as positive signs of a turnaround. Monitor the company's ability to translate these operational efficiencies into net profitability in the coming quarters.
HAL Q3 Net Profit Rises 29% YoY to ₹1,867 Cr; Declares ₹25 Interim Dividend
Hindustan Aeronautics Limited (HAL) reported a strong performance for Q3 FY26, with consolidated net profit growing 29.6% YoY to ₹1,866.66 crore. Revenue from operations increased by 10.6% YoY to ₹7,698.80 crore compared to the same quarter last year. The Board has declared a substantial first interim dividend of ₹25 per equity share (500% of face value) for FY 2025-26. The record date for the dividend is set for February 18, 2026, with payment to be completed by March 14, 2026.
முக்கிய அம்சங்கள்
Consolidated Net Profit increased 29.6% YoY to ₹1,866.66 crore in Q3 FY26.Revenue from operations grew 10.6% YoY to ₹7,698.80 crore.Declared first interim dividend of ₹25 per share on a face value of ₹5.Consolidated EPS for the quarter rose to ₹27.91 from ₹21.53 in Q3 FY25.Nine-month consolidated profit reached ₹4,919.48 crore, up 12% from ₹4,387.42 crore YoY.
👀 கவனிக்க வேண்டியவை
The strong double-digit profit growth and high dividend payout underscore HAL's robust operational health and cash position. Investors should maintain a positive outlook given the company's execution consistency and the attractive interim yield.
Shalby Q3 FY26 Results: Consolidated PAT Turns Positive at ₹13 Mn Despite Flat Revenue
Shalby Limited reported a mixed performance for Q3 FY26, with consolidated revenue remaining nearly flat at ₹2,794 million, a marginal 0.6% YoY decline. The company successfully turned around its consolidated bottom line, reporting a PAT of ₹13 million compared to a loss of ₹29.9 million in the year-ago period. However, operational metrics showed weakness, with inpatient counts down 7% and surgery counts down 8.5% YoY. Standalone EBITDA margins also faced significant pressure, contracting to 16.0% from 21.5% in Q3 FY25.
முக்கிய அம்சங்கள்
Consolidated PAT improved to ₹13 million from a loss of ₹29.9 million in Q3 FY25.Standalone EBITDA margins compressed by 550 bps YoY to 16.0% due to higher operating expenses.Total surgery counts declined by 8.5% YoY to 6,833, while ARPOB saw a marginal increase of 1.1% to ₹43,171.MedTech (Implant Business) contributed 10.88% to consolidated revenue, amounting to ₹303.8 million.Consolidated net debt stood at ₹4,086 million as of December 2025 with an annualized ROCE of 6.7%.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the decline in operational volumes and significant margin compression in the core standalone business. While the turnaround in consolidated PAT is positive, the high debt-to-equity ratio of 0.41x and low ROCE warrant a watchful approach.
Chalet Hotels has received a notice from the Greater Bengaluru Authority regarding alleged unpaid property tax dues of approximately Rs 39.56 crore, including interest and penalties. The notice pertains to the company's hotel complex in Whitefield, Bengaluru, and includes a proclamation for the sale of the property. Management asserts that all taxes have been paid regularly and believes the notice stems from a technical glitch or system error. The company is seeking legal recourse and expects a favorable resolution, noting that current business operations remain unaffected.
முக்கிய அம்சங்கள்
Notice issued by Greater Bengaluru Authority for alleged dues of ~Rs 39.56 crore including interest and penalties.The dispute involves the company's significant hotel and commercial complex in Whitefield, Bengaluru.Company maintains that all tax demands have been paid in a timely manner and suspects a technical glitch.Chalet Hotels is initiating legal action to resolve the matter and expects no impact on operations.The company became aware of the notice through a local newspaper article and subsequent website verification.
👀 கவனிக்க வேண்டியவை
Investors should monitor for further updates regarding the legal stay of the notice or official clarification from the Bengaluru Authority. While the company claims this is a technical error, the threat of property sale makes this a key development to track.
Shalby Q3 PAT Drops 34% YoY to ₹138 Mn; Board Approves ₹59.6 Cr Investment in Subsidiary
Shalby Limited reported a weak financial performance for Q3 FY26, with standalone Net Profit declining 33.9% YoY to ₹137.91 million. Revenue from operations remained largely stagnant with a marginal 2.4% YoY decline to ₹2,152.36 million. The Board has approved a significant capital commitment of ₹59.60 crore to subscribe to a rights issue by its subsidiary, PK Healthcare Private Limited. Additionally, the company is streamlining its structure by closing its non-operational step-down subsidiary, Ningen Lifecare Private Limited.
முக்கிய அம்சங்கள்
Standalone Net Profit fell 33.9% YoY to ₹137.91 million from ₹208.58 million in the previous year's quarter.Revenue from operations decreased to ₹2,152.36 million compared to ₹2,206.40 million in Q3 FY25.Profit Before Tax (PBT) saw a sharp decline of 38.8% YoY, dropping to ₹218.72 million.Approved investment of ₹59.60 crore to acquire 5.96 crore shares in subsidiary PK Healthcare Private Limited.Initiated strike-off process for step-down subsidiary Ningen Lifecare Private Limited due to lack of operations.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company faces significant margin contraction and declining profitability. Monitor the performance of the subsidiary PK Healthcare to see if the ₹59.6 crore investment yields better consolidated returns.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
